Market Overview

iCAN:Israel-Cannabis Continues to Accelerate Cannabis Innovation, Signs MoU With New Israeli Medical Cannabis Company Yom Chai to Develop and Clinically Validate Suppository Based Cannabis Treatments

Share:

iCAN:Israel-Cannabis Continues to Accelerate Cannabis Innovation, Signs MoU With New Israeli Medical Cannabis Company Yom Chai to Develop and Clinically Validate Suppository Based Cannabis Treatments

PR Newswire

TEL AVIV, Israel, Aug. 13, 2018 /PRNewswire/ -- iCAN:Israel-Cannabis is pleased to announce that it has entered into a Memorandum of Understanding ("MoU") with Yom Chai, Ltd to co-found the development and clinical validation of a range of cannabis based products.

Yom Chai has deep experience in the U.S. retail cannabis market opening and running dispensaries and production facilities as well as providing consulting services to a wide range of North American cannabis businesses.

Expanding its work in the industry with iCAN, Yom Chai, in collaboration with leading American and Israeli scientists and medical professionals is initially developing a formulated suppository targeting people suffering from Crohn's Disease and will develop various targeted cannabis formulations including treatment for children and adults with Autism.

iCAN will be supporting Yom Chai by combining its unique access to innovation and technology with unmatched industry insights and international connections.  The signing of this MOU provides iCAN with a combination of revenue, equity and future royalties and represents a further achievement of the company's objective be at the center of cannabis innovation.

"We are excited to join the portfolio of companies at iCAN and their global network of innovative companies to assist in the development of world class medical treatments," said Scot Albert, CEO of Yom Chai.

Saul Kaye, CEO of iCAN: Israel-Cannabis said, "Israel boasts the leading clinical researchers in Crohn's Disease and Autism, so it will be possible to leverage the local medical cannabis ecosystem to bring Yom Chai's products to patients as quickly as possible."

About iCAN: Israel-Cannabis

iCAN is a globally recognized Israeli company focused on the medical cannabis industry. iCAN operates across all verticals: consulting, business development, mentoring, investment strategy, network and media, compliance, and regulation, CRO, commercialization, formulation, and international distribution.  iCAN produces CannaTech, the global leader in international medical cannabis conferences. For more about iCAN click here.

About Yom Chai

Yom Chai's objective is to conduct scientific trials in Israel utilizing various cannabinoid profiles with the goal of realizing multiple successful discoveries. Yom Chai's goal is to bridge the gap between patients and doctors to bring scientifically proven products to market.  For more information on Yom Chai please visit us at www.yomchai.com.

Interested in knowing more or developing your own cannabis product please contact us at endoCRO@israel-cannabis.com

For further information contact Laura Kam at laura@kamgs.com +972-54-806-8613.

 

Cision View original content:http://www.prnewswire.com/news-releases/icanisrael-cannabis-continues-to-accelerate-cannabis-innovation-signs-mou-with-new-israeli-medical-cannabis-company-yom-chai-to-develop-and-clinically-validate-suppository-based-cannabis-treatments-300695938.html

SOURCE iCAN: Israel-Cannabis

View Comments and Join the Discussion!